STAAR Surgical Co (STAA) Stock AnalysisSTAAStock AnalysisSTAAR Surgical Co

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also markets and sells an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company's principal products are ICLs used in refractive surgery, including its EVO family of lenses. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).

STAAR Surgical Co is not a good buy right now due to its current price of $22.11 being above the target price of $19 set by UBS, indicating potential downside. Additionally, the RSI is at a low 23.217, suggesting the stock is oversold, but this could reflect ongoing market concerns rather than a buying opportunity. The recent 5-day change of -4.45% and 1-year change of -20.30% further highlight the stock's downward trend, making it a risky investment at this time.

5 analysts cover STAA: 3 rate it Buy, 2 Hold and 0 Sell. The average price target is 30.75.